皮动蛋白在结直肠癌中的表达及其与临床病理和预后参数的关系
该研究采用免疫组化检测319例结直肠癌患者组织芯片中皮动蛋白(cortactin)的表达,比较癌组织与正常结直肠黏膜的阳性表达率,并分析其与临床病理特征及生存的关系。结果示癌组织阳性表达率61.1%(195/319)高于正常黏膜5.6%(18/319,P<0.001),在Ⅱ~Ⅲ期患者中皮动蛋白阳性表达与较差的无病生存(P=0.036)和总生存(P=0.043)有关。
要点
- 癌组织皮动蛋白阳性表达率为61.1%(195/319),正常结直肠黏膜为5.6%(18/319,P<0.001)。
- Ⅱ~Ⅲ期患者中皮动蛋白阳性表达与较差的无病生存(P=0.036)和总生存(P=0.043)有关。
- Ⅱ~Ⅲ期患者术后辅助治疗与无病生存(P=0.007)和总生存(P=0.015)有关。
核心结论
- 皮动蛋白在结直肠癌组织中表达,在Ⅱ~Ⅲ期结直肠癌患者中,皮动蛋白是一个潜在的预后因子。
研究设计与样本
- 采用免疫组化技术检测组织芯片中皮动蛋白的表达,样本为2006—2009年于中国医学科学院肿瘤医院确诊为结直肠癌并接受治疗的患者319例,检测正常结直肠黏膜组织和结直肠癌组织。
- 生存分析采用Kaplan-Meier法和Log rank检验,多因素分析采用Cox比例风险回归模型。
主要发现
- 皮动蛋白在结直肠癌组织和正常结直肠黏膜组织中的阳性表达率分别为61.1%(195/319)和5.6%(18/319,P<0.001)。
- T分期、N分期、美国癌症联合委员会(AJCC)分期、肿瘤分化程度、神经侵犯和术前癌胚抗原(CEA)水平与皮动蛋白表达状态有关(均P<0.05)。
- 在Ⅱ~Ⅲ期患者中,皮动蛋白阳性表达与较差的无病生存(P=0.036)和总生存(P=0.043)有关。
- 对于Ⅱ~Ⅲ期结直肠癌患者,术后辅助治疗与无病生存(P=0.007)和总生存(P=0.015)有关。
- 脉管瘤栓、病理类型、术前CEA水平和皮动蛋白表达状态为无病生存的独立影响因素(均P<0.05),年龄、AJCC分期、术前CEA水平和皮动蛋白表达状态是总生存的独立影响因素(均P<0.05)。
临床怎么用
- 原文结论仅指出皮动蛋白在Ⅱ~Ⅲ期结直肠癌患者中是一个潜在的预后因子,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of cortactin in colorectal cancer and its correlation with clinicopathological parameters and prognosis. Methods: The expressions of cortactin in normal colorectal mucosal tissue and colorectal cancer tissue in paraffin-embedded tissue microarray from 319 patients who were diagnosed as colorectal cancer and treated in Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2009 was detected by immunohistochemistry. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox proportional risk regression model was used for multivariate analysis. Results: The positive expression rates of cortactin in colorectal cancer tissue and normal colorectal mucosal tissue were 61.1% (195/319) and 5.6% (18/319, P<0.001), respectively. T-stage, N-stage, American Joint Committee on Cancer (AJCC) stage, degree of tumor differentiation, neural invasion and preoperative carcinoembryonic antigen (CEA) levels were associated with the expression of cortactin (P<0.05). The positive expression of cortactin was associated with poorer disease-free survival (P=0.036) and overall survival (P=0.043), and the effect was more significant in patients with stage Ⅱ to Ⅲ. For patients with stage Ⅱ-Ⅲ colorectal cancer, postoperative adjuvant therapy was associated with disease-free survival (P=0.007) and overall survival (P=0.015). The vascular tumor embolus, pathological type, preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival (P<0.05). The age, AJCC stage, preoperative CEA level and cortactin expression were independent influencing factors for overall survival (P<0.05). Preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival and overall survival (P<0.05). Conclusion: Cortactin is expressed in colorectal cancer and in stage Ⅱ-Ⅲ patients, it is a potential predictor of colorectal cancer prognosis. 目的: 探讨皮动蛋白(cortactin)在结直肠癌中的表达及其与临床病理特征和预后的关系。 方法: 选取2006—2009年于中国医学科学院肿瘤医院确诊为结直肠癌并接受治疗的患者319例,利用免疫组化技术检测组织芯片中正常结直肠黏膜组织和结直肠癌组织中cortactin的表达,生存分析采用Kaplan-Meier法和Log rank检验,多因素分析采用Cox比例风险回归模型。 结果: cortactin在结直肠癌组织和正常结直肠黏膜组织中的阳性表达率分别为61.1%(195/319)和5.6%(18/319,P<0.001)。T分期、N分期、美国癌症联合委员会(AJCC)分期、肿瘤分化程度、神经侵犯和术前癌胚抗原(CEA)水平与cortactin表达状态有关(均P<0.05)。在Ⅱ~Ⅲ期患者中,cortactin阳性表达与较差的无病生存(P=0.036)和总生存(P= 0.043)有关。对于Ⅱ~Ⅲ期结直肠癌患者,术后辅助治疗与无病生存(P=0.007)和总生存(P=0.015)有关。脉管瘤栓、病理类型、术前CEA水平和cortactin表达状态为无病生存的独立影响因素(均P<0.05),年龄、AJCC分期、术前CEA水平和cortactin表达状态是总生存的独立影响因素(均P<0.05),术前CEA水平和cortactin表达状态为无病生存和总生存的独立影响因素(均P<0.05)。 结论: cortactin在结直肠癌组织中表达,在Ⅱ~Ⅲ期结直肠癌患者中,cortactin是一个潜在的预后因子。.
引用
- Zhao CD, Zhou SC, Su H, et al. [The expression of cortactin in colorectal cancer and its relationship with clinicopathological and prognostic parameters]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35316877. doi:10.3760/cma.j.cn112152-20210226-00172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。